AllianceBernstein Holding (NYSE:AB) reported quarterly earnings of $0.71 per share which met the analyst consensus estimate. This is a 21.98 percent decrease over earnings of $0.91 per share from the same period last year.
Marching Towards FDA Approval: Dermavant’s Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission
Dermavant Sciences, a Roivant Sciences (NASDAQ: ROIV) company, announced results from ADORING 1 Phase 3 trial of topical Vtama (tapinarof) cream, 1% in adults and pediatric subjects down to 2 years old with moderate to